前收盘价格 | 2.30 |
收盘价格 | 2.29 |
成交量 | 1,273,147 |
平均成交量 (3个月) | 1,492,843 |
市值 | 1,609,312,256 |
市盈率 (P/E TTM) | 233.00 |
预期市盈率 (P/E Forward) | 135.14 |
价格/销量 (P/S) | 13.94 |
股市价格/股市净资产 (P/B) | 19.64 |
52周波幅 | |
利润日期 | 23 Aug 2024 |
营业毛利率 | 5.10% |
营业利益率 (TTM) | 1.83% |
稀释每股收益 (EPS TTM) | 0.010 |
季度收入增长率 (YOY) | 54.50% |
总债务/股东权益 (D/E MRQ) | 21.32% |
流动比率 (MRQ) | 3.41 |
营业现金流 (OCF TTM) | 3.68 M |
杠杆自由现金流 (LFCF TTM) | -1.46 M |
资产报酬率 (ROA TTM) | 0.56% |
股东权益报酬率 (ROE TTM) | 7.65% |
市场趋势
短期 | 中期 | ||
行业 | Medical Devices (AU) | 混合的 | 混合的 |
Medical Devices (全球的) | 混合的 | 混合的 | |
股票 | POLYNOVO FPO [PNV] | - | - |
AIStockmoo 评分
分析师共识 | 0.0 |
内部交易活动 | NA |
价格波动 | 1.0 |
技术平均移动指标 | 2.5 |
技术振荡指标 | -0.5 |
平均 | 0.75 |
Polynovo earns most of its revenue from US sales of its NovoSorb Biodegradable Temporizing Matrix, or NovoSorb BTM. The product is a patented biodegradable synthetic scaffold to support the regeneration of the dermis when lost through surgery, trauma, burns, or other causes of tissue loss. Once the product is applied to a wound, it takes a few weeks for the dermal layer to fully integrate within the polymer scaffold before a clinician can delaminate the outer layer. A small wound would then close either naturally or with a dressing, while a larger wound would close through a split-skin graft or alternative product such as Avita’s RECELL. NovoSorb BTM then slowly degrades to harmless byproducts which are fully absorbed in roughly 18 months. |
|
部门 | Healthcare |
行业 | Medical Devices |
投资方式 | Small Growth |
内部持股比例 | 11.08% |
机构持股比例 | 18.60% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。
投资组合